About CEL-SCI
CEL-SCI is a company based in Vienna (United States) founded in 1983. It operates as a HealthTech. CEL-SCI offers products and services including Multikine and LEAPS. CEL-SCI operates in a competitive market with competitors including RefleXion, Brii Biosciences, SetPoint Medical, Affinivax and Osivax, among others.
- Headquarter Vienna, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website cel-sci.com
- Social LinkedIn X Facebook
- Legal Name Cel-Sci Corporation
- Net Profit-$25.41 M (USD)5.61as on Sep 30, 2025
- EBITDA-$20.92 M (USD)6.52as on Sep 30, 2025
- Latest Funding Round$10M (USD), Post-IPO
Jun 2020
- InvestorsHHS
& 7 more
Products & Services of CEL-SCI
CEL-SCI offers a comprehensive portfolio of products and services, including Multikine and LEAPS.
Multikine is developed for head and neck cancer treatment.
LEAPS is researched for autoimmune and infectious disease treatment.
Funding Insights of CEL-SCI
- Total Rounds 7
- Last Round Post-IPO — $10M
- First Round $4.4M
(Aug 2009)
- Investors Count 8
All 7 funding rounds of CEL-SCI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $10M | Post-IPO | – | – | – |
| Oct 2018 | $8M | Post-IPO | – | – | – |
| Sep 2018 | $5.44M | Post-IPO | – | – | – |
| Feb 2017 | $1M | Post-IPO | – | – | – |
| Jul 2014 | $1.72M | Grant | – | – | |
| Dec 2009 | $5M | Post-IPO | – | – | |
| Aug 2009 | $4.4M | Post-IPO | – | – |
8 investors in total: 8 institutional.
Investors in CEL-SCI
CEL-SCI has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Ascendiant Capital Markets and Iroquois Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment services are offered by Iroquois Capital Group. | – | iroquoiscg.com | Nashville, United States | |
- | – | paramountcapital.com | - | |
A family office focused on private equity and investments. | 1984 | alphacapital.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | ascendiant.com | - | |
Recollective is recognized as a Guided Discovery Platform for qualitative research. | – | recollective.com | Ottawa, Canada | |
Operates as a long/short equity hedge fund for strategic investment opportunities. | 2002 | midsummercapital.com | New York, United States | |
Provides investment management services specializing in portfolio construction and risk assessment. | 2006 | rockmorecapital.com | West Palm Beach, United States |
Investor details for CEL-SCI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CEL-SCI
3 people are tracked at CEL-SCI (3 in leadership).
| Name | Role | Group |
|---|---|---|
Geert Kersten | CEO & Director | Leadership |
Geert R. Kersten | Chief Executive Officer | Leadership |
Gavin de Windt | Director Of Operations & Investor Relations | Leadership |
Complete people profiles for CEL-SCI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CEL-SCI
CEL-SCI is a publicly listed company on the AMEX with ticker symbol CVM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jan 1987
- Listed onNYSEAMERICAN: CVM
- Listed entityCel-Sci Corporation
- Exchange sectorHealth technology
- ISINUS1508377066
- Share price$1.94 (-0.51% on the day) · 2026-10-09
- Market capitalisation$34.1M
- EPS (diluted, trailing year)$-2.58
- Volume (last session)255,449
Financials of CEL-SCI
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$25.4M | -$20.9M |
| 2024 | – | -$26.9M | -$22.4M |
| 2023 | – | -$32.2M | -$27.5M |
| 2022 | – | -$36.7M | -$32.2M |
| 2021 | – | -$36.4M | -$35.7M |
Detailed financial statements for CEL-SCI
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CEL-SCI
4 dated milestones of CEL-SCI across 37 years, from founding to its latest funding, stage changes and deals.
- Founded CEL-SCI is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $4.4M.
- Funding Latest funding round, Post-IPO, of $10.0M.
Competitors of CEL-SCI
CEL-SCI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RefleXion, Brii Biosciences, SetPoint Medical, Affinivax and Osivax, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| reflexion.com | 2009 | Hayward, United States | $553.91M | 257 | Biology-guided radiotherapy systems are provided for cancer treatment. | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| setpointmedical.com | 2006 | Santa Clarita, United States | $363.17M | 46 | Implantable neuromodulation devices are developed for inflammatory diseases. | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| osivax.com | 2017 | Lyon, France | $42.21M | – | Vaccines against mutating pathogens are developed using nanoparticle technology. | |
| alphatau.com | 2015 | Tel Aviv, Israel | $55M | – | Radiotherapy technique for solid tumors is developed using alpha-emitting seeds. | |
| diamyd.com | 1994 | Stockholm, Sweden | – | – | Therapies for autoimmune diabetes treatment and prevention are developed. | |
| cstonepharma.com | 2016 | Shanghai, China | $410M | – | Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | |
| affiris.com | 2003 | Vienna, Austria | $82.65M | – | AFFiRiS is focused on developing immunotherapies for chronic diseases. | |
| imcyse.com | 2010 | Liege, Belgium | $57.25M | 48 | A portfolio of pharmaceuticals is developed against multiple immune-mediated diseases. |
Detailed competitors of CEL-SCI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CEL-SCI
The website of CEL-SCI (cel-sci.com) receives about 3.2K visits a month and ranks #5,603,385 among all websites worldwide, #6,164 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▲ 4.7% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,603,385
among all websites
- Category rank#6,164
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit28 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with CEL-SCI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vblrx.com | 100% | 2.5K | #3,978,257 | View details | |
| neuroderm.com | 100% | 2.8K | #5,643,423 | View details | |
| leespharm.com | 99% | – | #12,343,912 | View details | |
| viedoc.com | 98% | 21.5K | #713,207 | View details | |
| ichorms.com | 98% | 5.3K | #8,265,520 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for CEL-SCI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cel-Sci
Complete news archive for CEL-SCI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CEL-SCI
10 companies that operate in the same segment as CEL-SCI (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CEL-SCI
CEL-SCI was founded in 1983 and raised its 1st funding round 26 years after it was founded.
CEL-SCI is headquartered in Vienna, United States.
Geert Kersten is the current CEO of CEL-SCI.
CEL-SCI Corporation is engaged in the research and development of immunotherapy products for cancer, autoimmune, and infectious diseases. The company is recognized for its pioneering work in cancer immunotherapy, particularly through its lead product, Multikine, which is tested in a global Phase III clinical trial for head and neck cancer. The trial, involving 928 patients, demonstrated significant survival benefits when administered before standard treatments. Additionally, LEAPS technology is being developed for rheumatoid arthritis and other conditions. The companys efforts are directed at leveraging the immune system to address unmet medical needs in these critical health sectors.
CEL-SCI's top competitors include RefleXion, Brii Biosciences and SetPoint Medical.
CEL-SCI offers Multikine and LEAPS.
Yes, CEL-SCI is publicly traded on AMEX under the ticker symbol CVM.
CEL-SCI has 8 investors. Key investors include HHS, Ascendiant Capital Markets, Iroquois Capital Group, Recollective, and Midsummer Capital.
CEL-SCI operates through Cel-Sci Corporation.